CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,623 enrolled
Drug / intervention
CDB-2914drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00411684
NCT00411684Phase 3Completed
CompareCT.gov

A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CDB-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Sex

HRA Pharma·interventional·Posted Dec 14, 2006·Updated Sep 21, 2021

In Brief

A Phase 3 clinical trial evaluating CDB-2914 for Emergency Contraception. Completed, enrolled 1,623 participants across 17 sites.

Detailed Summary

The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEmergency Contraception
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 14, 2006
Enrollment StartNov 1, 2006
Primary CompletionApr 8, 2008
Study CompletionJun 5, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.6 years ago

Interventions

CDB-2914drug